Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 4Wilms Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liver Neoplasms 2Kidney Neoplasms 2Astrocytoma 2Testicular Neoplasms 1Teratoma 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrent Uterine Corpus Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Optic Nerve Glioma 1Oligodendroglioma 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Eosinophilic, Acute 1Leukemia 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Familial ependymoma 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × ixabepilone × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡